Revenue: As of FY2025, the actual value is USD 1.005 M.EPS: As of FY2025, the actual value is USD -11.73.EBIT: As of FY2025, the actual value is USD -7.855 M.The company operates and manages its business as a single identifiable segment, focusing on the development and marketing of new medicines for infectious diseases .<h4>Revenue</h4><ul><li>Product Revenues - net of Discounts and Rebates increased by 65.49% to $1,005,471 in 2025 from $607,574 in 2024 . U.S. pharmaceutical distributors accounted for 92% of total net product sales in 2025 (95% in 2024), while Kodatef sales to the Australian distributor accounted for 6% (5% in 2024) . Discounts and rebates totaled $476,430 in 2025, compared to $476,218 in 2024 .</li><li>Research Revenues significantly increased by 447.13% to $403,624 in 2025 from $73,771 in 2024, primarily due to a new USAMMDA contract for Arakoda supply chain upgrade support ($298,868 in 2025 vs $12,994 in 2024) and $89,302 from the University of Kentucky .</li><li>Net Revenue was $627,400 in 2025, up from $296,580 in 2024 .</li></ul><h4>Operational Metrics</h4><ul><li>Cost of Revenues increased by 103.16% to $781,695 in 2025 from $384,765 in 2024, partly due to higher product sales and $445,181 in inventory write-offs for expiring inventory in 2025 (vs $22,046 in 2024) .</li><li>Gross Profit was $223,776 in 2025, a 0.43% increase from $222,809 in 2024 .</li><li>Gross Margin decreased from 36.67% in 2024 to 22.26% in 2025 .</li><li>Research and Development expenses decreased by - $2,880,370 (-57.76%) to $2,106,156 in 2025 from $4,986,526 in 2024, mainly due to non-cash charges of $3,225,000 recognized in 2024 . Direct trial-related costs for the babesiosis trial were $1,496,148 in 2025, compared to $1,359,532 in 2024 .</li><li>General and Administrative Expenses increased by $1,254,588 (24.97%) to $6,279,823 in 2025 from $5,025,235 in 2024, driven by higher legal and professional fees, investor outreach, advertising, promotion expenses, and increased stock-based compensation costs .</li><li>Total Operating Expenses were $8,385,979 in 2025, a -16.24% decrease from $10,011,761 in 2024 .</li><li>Loss from Operations was - $7,758,579 in 2025, an improvement from - $9,715,181 in 2024 .</li><li>Interest Expense was - $7,805 in 2025, similar to - $7,912 in 2024 .</li><li>Change in Fair Value of Derivative Liabilities resulted in a gain of $266,089 in 2025, a decrease from the $1,665,966 gain in 2024 .</li><li>Other Income, net was $131,970 in 2025, up from $101,464 in 2024 .</li><li>Net Loss attributed to 60 Degrees Pharmaceuticals, Inc. improved to - $7,365,158 in 2025 from - $7,947,107 in 2024 .</li><li>Net Loss per Common Share (Basic and Diluted) was - $11.73 in 2025, an improvement from - $74.17 in 2024 .</li></ul><h4>Cash Flow</h4><ul><li>Net Cash Used in Operating Activities increased to - $6,849,022 in 2025 from - $5,648,088 in 2024 .</li><li>Net Cash Provided by (Used in) Investing Activities was $254,916 in 2025, a significant change from - $1,889,114 in 2024, primarily due to maturities of short-term investments .</li><li>Net Cash Provided by Financing Activities was $6,437,691 in 2025, a decrease from $7,053,571 in 2024 .</li></ul><h4>Unique Metrics</h4><ul><li>Arakoda Sales Volume (16-ct box equivalents) increased by 12% to 5,724 units in 2025 from 5,119 units in 2024 .</li><li>Kodatef sales volume in Australia showed less than 1% year-over-year growth, with 1,854 boxes sold in 2025 compared to 1,850 boxes in 2024 .</li><li>Arakoda sales volume in Europe by Scandinavian Biopharma increased to 353 boxes in 2025 from 147 boxes in 2024, driven by greater interest in treating babesiosis .</li></ul><h4>Outlook / Guidance</h4>60 Degrees Pharmaceuticals, Inc. estimates it will have sufficient funds to remain viable through September 30, 2026, assuming no additional capital raises . The company plans to fund operations through debt/advances, private placement of restricted securities, and stock issuance until profitability or a business combination is achieved . However, the lack of assurance for successfully raising additional capital or achieving profitability raises substantial doubt about its ability to continue as a going concern .

60 DEGREES PHARMACEUTICALS INC C/WTS 12/07/2028 (TO PUR COM) | 10-K: FY2025 Revenue: USD 1.005 M